Released May 8, 2025, after the close
10-Q filed May 12, 2025, 42 days after period end · 0001299130-25-000102
Q1 2025 · 10-Q
Revenue$37.15M$37.15M −4.3% vs Q1 2024−5.3% vs Q4 2024
Net Income-$426.08M-$426.08M N/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$1.44-$1.44 N/M vs Q1 2024no prior Q4 2024 on file
Gross Profit-$1,371,000N/M
Operating Income-$428,934,000N/M
Operating Cash Flow-$44,056,000N/M
Free Cash Flowderived-$45,445,000N/M
Margins · derived
Gross margin-3.7%−32.8 pt vs Q1 2024
Operating margin-1154.5%−944.9 pt vs Q1 2024
Net margin-1146.8%−945.4 pt vs Q1 2024
What the release said
The release
Same quarter
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Revenue | $37.15M | $38.81M | $38.90M | $33.17M |
| Net Income | -$426.08M | -$78.18M | -$88.02M | -$81.50M |
| EPS Diluted | -$1.44 | -$0.29 | -$0.36 | -$0.37 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pacific Biosciences of California, Inc. · CIK 1299130 · Engraved from SEC EDGAR